Male adolescent fertility preservation
Today, most male adolescent cancer patients will survive their initial diagnoses. Unfortunately, most of these patients are not currently provided adequate fertility preservation counseling or care.
Jared L. Moss, M.D., Andrew Wonho Choi, B.S., Mary Kate Fitzgerald Keeter, M.P.H., Robert E. Brannigan, M.D.
Volume 105, Issue 2, Pages 267-273
Until the 1960s, few adolescents and young adults (AYAs) survived their initial cancer diagnoses. Now, ∼12,400 AYA patients are diagnosed with cancer each year, and almost 80% will now achieve a long-term cure. This dramatic improvement in survival is primarily due to multimodal treatments and combined chemotherapeutic regimens. Unfortunately, the increase in survival is often accompanied by treatment-related toxicities due to chemotherapy, radiation therapy, and surgical procedures. Despite guidelines published by the American Society of Clinical Oncology and numerous other professional organizations, high percentages of male AYA oncology patients are not properly counseled regarding their fertility preservation options before cancer treatment. Although administering fertility preservation care to adolescent males can be challenging in many ways, numerous studies show that this care can be delivered with high degrees of success and high levels of patient and parent satisfaction. The key to this success at many institutions has been the implementation of formalized integrated fertility preservation programs with infrastructure geared toward the delivery of comprehensive expedited care.